No. Instead, Doc seems to understand how that could be applied.
What I would say is that if there is something above and beyond TFF for any possible DCVax-L improvement, I'd think it would have to do with time/extent of activation and/or cytokine levels. I don't know if TFF was added to the trial in Germany, but I think If it was, there was potentially another optimization as well. Dunno. Regardless if you want high cytokine secretion from Direct at the tumor site, you still want that high cytokine secretion in the lymph as well, per the patent, to help stimulate the t-cell response.
Ergo, you'd want both DCvax-Direct and DCVax-L achieving certain levels of cytokine production when they get to the lymph. It could be with brain cancer, DCVax-L therapy, you want a goldilocks secretion level in the lymph nodes. Not too strong and not too weak. Just by adding TFF, you get far more dense antigen expression. If the other cytokine secretion parameters are taken into account then....
News 
Market Data 
Discover 
AI
